Vestronidase

Breastfeeding
  • TRADE NAME: Mepsevii (Ultragenyx)
  • INDICATIONS: Mucopolysaccharidosis VII (Sly syndrome)
  • CLASS: Enzyme replacement
  • HALF-LIFE: 51–213 minutes

FDA APPROVAL DATE: 11/15/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
No available data to determine drug-associated risk

ANAPHYLAXIS

See full prescribing information for complete boxed warning.

Our database has 11 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
LOCAL


Page last updated 04/09/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric